AstraZeneca, Daiichi Sankyo TROP2 ADC Wins China Approval in Triple-Negative Breast Cancer

This approval matters less for the TNBC label itself than for the sequencing signal: a TROP2 ADC reaching first-line use in China, ahead of PD-1/PD-L1-ineligible patients, positions the class where chemo has long been the default. It affects AstraZeneca and Daiichi Sankyo's competitive standing against rival TROP2 programs and gives Chinese oncologists a targeted option for a population that immunotherapy trials largely exclude. Whether first-line adoption follows approval, and how broadly PD-1/PD-L1-ineligible status is read in practice, is the open question.